The University of Chicago Header Logo

Connection

Michael Davidson to Schizophrenic Psychology

Back to Details
This is a "connection" page, showing publications Michael Davidson has written about Schizophrenic Psychology.
Michael Davidson
Connection Strength
5.231
Schizophrenic Psychology
  1. Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia. Am J Psychiatry. 2017 12 01; 174(12):1195-1202.
    View in: PubMed
    Score: 0.507
  2. A population-based longitudinal study of suicide risk in male schizophrenia patients: Proximity to hospital discharge and the moderating effect of premorbid IQ. Schizophr Res. 2015 Dec; 169(1-3):159-164.
    View in: PubMed
    Score: 0.448
  3. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res. 2007 Jul; 93(1-3):117-30.
    View in: PubMed
    Score: 0.249
  4. Premorbid functioning and treatment response in recent-onset schizophrenia. Br J Psychiatry. 2006 Jul; 189:31-5.
    View in: PubMed
    Score: 0.235
  5. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. Am J Psychiatry. 2005 Oct; 162(10):1888-95.
    View in: PubMed
    Score: 0.223
  6. Prevalence of prominent and predominant negative symptoms across different criteria for negative symptom severity and minimal positive symptoms: A comparison of different criteria. Schizophr Res. 2024 09; 271:246-252.
    View in: PubMed
    Score: 0.206
  7. Who has poor insight, my patient suffering from schizophrenia or myself? Eur Neuropsychopharmacol. 2023 03; 68:27-29.
    View in: PubMed
    Score: 0.185
  8. Personal and social adjustment effects of roluperidone in patients with schizophrenia and negative symptoms: Results from an exploratory outcome of a randomized placebo-controlled trial. Schizophr Res. 2019 09; 211:103-104.
    View in: PubMed
    Score: 0.146
  9. The association between adaptive and cognitive deficits in geriatric chronic schizophrenic patients. Schizophr Res. 1997 Oct 30; 27(2-3):211-8.
    View in: PubMed
    Score: 0.129
  10. Limitations of controlled augmentation trials in schizophrenia. Biol Psychiatry. 1997 Jul 15; 42(2):138-43.
    View in: PubMed
    Score: 0.126
  11. Verbal fluency deficits in geriatric and nongeriatric chronic schizophrenic patients. J Neuropsychiatry Clin Neurosci. 1997; 9(4):584-90.
    View in: PubMed
    Score: 0.122
  12. Cognitive impairment and negative symptoms in geriatric chronic schizophrenic patients: a follow-up study. Schizophr Res. 1996 Dec 15; 22(3):223-31.
    View in: PubMed
    Score: 0.121
  13. Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. Am J Psychiatry. 2017 Mar 01; 174(3):216-229.
    View in: PubMed
    Score: 0.121
  14. Symptom stability in geriatric chronic schizophrenic inpatients: a one-year follow-up study. Biol Psychiatry. 1996 Jan 15; 39(2):92-9.
    View in: PubMed
    Score: 0.114
  15. Developmental Trajectories of Impaired Community Functioning in Schizophrenia. JAMA Psychiatry. 2016 Jan; 73(1):48-55.
    View in: PubMed
    Score: 0.114
  16. Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia. Schizophr Bull. 2016 Jan; 42(1):19-33.
    View in: PubMed
    Score: 0.111
  17. The cost of cognitive impairment in schizophrenia. Schizophr Res. 1995 Sep; 17(1):1-3.
    View in: PubMed
    Score: 0.111
  18. Cognitive functioning in chronically hospitalized schizophrenic patients: age-related changes and age disorientation as a predictor of impairment. Schizophr Res. 1995 Sep; 17(1):15-24.
    View in: PubMed
    Score: 0.111
  19. The longitudinal stability of cognitive impairment in schizophrenia. Mini-mental state scores at one- and two-year follow-ups in geriatric in-patients. Br J Psychiatry. 1995 May; 166(5):630-3.
    View in: PubMed
    Score: 0.109
  20. The puzzle of processing speed, memory, and executive function impairments in schizophrenia: fitting the pieces together. Biol Psychiatry. 2015 Dec 01; 78(11):786-93.
    View in: PubMed
    Score: 0.107
  21. Memory functions in geriatric chronic schizophrenic patients: a neuropsychological study. J Neuropsychiatry Clin Neurosci. 1995; 7(2):207-12.
    View in: PubMed
    Score: 0.106
  22. Predictors of response to neuroleptic treatment in schizophrenia. Psychiatr Clin North Am. 1993 Jun; 16(2):313-38.
    View in: PubMed
    Score: 0.095
  23. Comorbid substance abuse in first-episode schizophrenia: effects on cognition and psychopathology in the EUFEST study. Schizophr Res. 2013 Jun; 147(1):132-139.
    View in: PubMed
    Score: 0.094
  24. Leukotomy and aging in chronic schizophrenia: a followup study 40 years after psychosurgery. Schizophr Bull. 1993; 19(4):723-32.
    View in: PubMed
    Score: 0.092
  25. Dedifferentiation and substitute strategy: deconstructing the processing-speed impairment in schizophrenia. Schizophr Res. 2012 Dec; 142(1-3):129-36.
    View in: PubMed
    Score: 0.091
  26. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia. J Clin Psychiatry. 2012 Jun; 73(6):e728-34.
    View in: PubMed
    Score: 0.089
  27. Effects of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrations. Arch Gen Psychiatry. 1991 Oct; 48(10):910-3.
    View in: PubMed
    Score: 0.085
  28. Increments in plasma homovanillic acid concentrations after neuroleptic discontinuation are associated with worsening of schizophrenic symptoms. Prog Neuropsychopharmacol Biol Psychiatry. 1990; 14(6):879-84.
    View in: PubMed
    Score: 0.075
  29. What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it? Schizophr Bull. 2010 May; 36(3):504-9.
    View in: PubMed
    Score: 0.068
  30. Network intervention analysis indicates that roluperidone achieves its effect on negative symptoms of schizophrenia by targeting avolition. Eur Neuropsychopharmacol. 2024 Oct; 87:18-23.
    View in: PubMed
    Score: 0.051
  31. A population-based cohort study of premorbid intellectual, language, and behavioral functioning in patients with schizophrenia, schizoaffective disorder, and nonpsychotic bipolar disorder. Am J Psychiatry. 2002 Dec; 159(12):2027-35.
    View in: PubMed
    Score: 0.046
  32. Rapid onset of therapeutic effect of risperidone versus haloperidol in a double-blind randomized trial. J Clin Psychiatry. 2001 May; 62(5):343-6.
    View in: PubMed
    Score: 0.041
  33. A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. On behalf of the Risperidone Working Group. Int J Geriatr Psychiatry. 2000 Jun; 15(6):506-14.
    View in: PubMed
    Score: 0.039
  34. Cognitive decline in late-life schizophrenia: a longitudinal study of geriatric chronically hospitalized patients. Biol Psychiatry. 1999 Jan 01; 45(1):32-40.
    View in: PubMed
    Score: 0.035
  35. The effect of minocycline on symptoms in schizophrenia: Results from a randomized controlled trial. Schizophr Res. 2019 04; 206:325-332.
    View in: PubMed
    Score: 0.035
  36. Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites. Am J Psychiatry. 1998 Aug; 155(8):1080-6.
    View in: PubMed
    Score: 0.034
  37. Cognitive impairment in geriatric chronic schizophrenic patients: a cross-national study in New York and London. Int J Geriatr Psychiatry. 1997 Oct; 12(10):1001-7.
    View in: PubMed
    Score: 0.032
  38. Symptom severity and cognitive impairment in chronically hospitalised geriatric patients with affective disorders. Br J Psychiatry. 1997 Apr; 170:369-74.
    View in: PubMed
    Score: 0.031
  39. Age-related differences in formal thought disorder in chronically hospitalized schizophrenic patients: a cross-sectional study across nine decades. Am J Psychiatry. 1997 Feb; 154(2):205-10.
    View in: PubMed
    Score: 0.031
  40. Social-Adaptive Functioning Evaluation (SAFE): a rating scale for geriatric psychiatric patients. Schizophr Bull. 1997; 23(1):131-45.
    View in: PubMed
    Score: 0.030
  41. Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale. Biol Psychiatry. 1996 Oct 15; 40(8):755-60.
    View in: PubMed
    Score: 0.030
  42. Cognitive functioning in late-life schizophrenia: a comparison of elderly schizophrenic patients and patients with Alzheimer's disease. Am J Psychiatry. 1996 Oct; 153(10):1274-9.
    View in: PubMed
    Score: 0.030
  43. Clinical characteristics of Kraepelinian schizophrenia: replication and extension of previous findings. Am J Psychiatry. 1996 Jun; 153(6):806-11.
    View in: PubMed
    Score: 0.029
  44. Cognitive function and biological correlates of cognitive performance in schizotypal personality disorder. Psychiatry Res. 1995 Nov 29; 59(1-2):127-36.
    View in: PubMed
    Score: 0.028
  45. A pen-and-paper human analogue of a monkey prefrontal cortex activation task: spatial working memory in patients with schizophrenia. Schizophr Res. 1995 Sep; 17(1):25-33.
    View in: PubMed
    Score: 0.028
  46. Severity of symptoms in chronically institutionalized geriatric schizophrenic patients. Am J Psychiatry. 1995 Feb; 152(2):197-207.
    View in: PubMed
    Score: 0.027
  47. Cortical cholinergic markers in schizophrenia. Schizophr Res. 1994 May; 12(2):137-44.
    View in: PubMed
    Score: 0.025
  48. Neuropsychological correlates of central monoamine function in chronic schizophrenia: relationship between CSF metabolites and cognitive function. Schizophr Res. 1994 Feb; 11(3):217-24.
    View in: PubMed
    Score: 0.025
  49. Empirical assessment of the factorial structure of clinical symptoms in schizophrenia: negative symptoms. Psychiatry Res. 1992 Nov; 44(2):153-65.
    View in: PubMed
    Score: 0.023
  50. Assessment of dementia in elderly schizophrenics with structured rating scales. Schizophr Res. 1992 Apr; 7(1):85-90.
    View in: PubMed
    Score: 0.022
  51. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry. 1991 Nov; 148(11):1474-86.
    View in: PubMed
    Score: 0.021
  52. Continuous performance tests in schizophrenic patients: stimulus and medication effects on performance. Psychiatry Res. 1991 Apr; 37(1):47-56.
    View in: PubMed
    Score: 0.020
  53. Changes in plasma homovanillic acid concentrations in schizophrenic patients following neuroleptic discontinuation. Arch Gen Psychiatry. 1991 Jan; 48(1):73-6.
    View in: PubMed
    Score: 0.020
  54. A comparison of plasma homovanillic acid concentrations in schizophrenic patients and normal controls. Arch Gen Psychiatry. 1988 Jun; 45(6):561-3.
    View in: PubMed
    Score: 0.017
  55. Impaired reading comprehension and mathematical abilities in male adolescents with average or above general intellectual abilities are associated with comorbid and future psychopathology. J Nerv Ment Dis. 2007 Nov; 195(11):883-90.
    View in: PubMed
    Score: 0.016
  56. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry. 2005 May; 162(5):947-53.
    View in: PubMed
    Score: 0.014
  57. Convergence of cognitive and adaptive decline in late-life schizophrenia. Schizophr Res. 1999 Jan 04; 35(1):77-84.
    View in: PubMed
    Score: 0.009
  58. Alzheimer disease and related neurodegenerative diseases in elderly patients with schizophrenia: a postmortem neuropathologic study of 100 cases. Arch Gen Psychiatry. 1998 Mar; 55(3):205-11.
    View in: PubMed
    Score: 0.008
  59. Neuropeptide deficits in schizophrenia vs. Alzheimer's disease cerebral cortex. Biol Psychiatry. 1996 Jan 15; 39(2):82-91.
    View in: PubMed
    Score: 0.007
  60. Validity and utility of the ADAS-L for measurement of cognitive and functional impairment in geriatric schizophrenic inpatients. J Neuropsychiatry Clin Neurosci. 1995; 7(1):76-81.
    View in: PubMed
    Score: 0.007
  61. Alzheimer's-disease-related protein in geriatric schizophrenic patients with cognitive impairment. Am J Psychiatry. 1993 Nov; 150(11):1726-7.
    View in: PubMed
    Score: 0.006
  62. Serotonin function and treatment response to clozapine in schizophrenic patients. Am J Psychiatry. 1993 Sep; 150(9):1337-42.
    View in: PubMed
    Score: 0.006
  63. Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia. Serotonin-dopamine interactions as a target for treatment. Arch Gen Psychiatry. 1993 Aug; 50(8):599-605.
    View in: PubMed
    Score: 0.006
  64. Haloperidol and clozapine treatment and their effect on M-chlorophenylpiperazine-mediated responses in schizophrenia: implications for the mechanism of action of clozapine. Psychopharmacology (Berl). 1993; 112(1 Suppl):S90-4.
    View in: PubMed
    Score: 0.006
  65. Time course and clinical predictors of treatment response in schizophrenia. Schizophr Res. 1991 Sep; 5(2):161-6.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.